Tivantinib is a Highly Selective c-Met Tyrosine Kinase Inhibitor for Hepatocellular Carcinoma Research
Tivantinib, a c-MET inhibitor, is investigated as a second-line treatment of hepatocellular carcinoma (HCC). It was shown that c-MET overexpression predicts its efficacy. However, recent evidence indicates that the anticancer…